Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma and increased the price target to $570.00 from $500.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors including Alnylam Pharma’s strong commercial performance and promising pipeline developments. The company reported significant growth in its TTR franchise, particularly with the U.S. launch of AMVUTTRA for ATTR-CM, which led to a substantial increase in revenue projections for 2025.
Alnylam’s late-stage pipeline is advancing well, with new trials and studies on track, reinforcing its position as a leader in RNAi therapeutics. The broad payer access and strong physician adoption of AMVUTTRA, alongside international regulatory approvals, further support the company’s growth prospects. These factors collectively underpin Trucchio’s confidence in Alnylam’s potential for continued success, justifying the Buy rating and increased price target.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $482.00 price target.